

The West Australian

Biotech Health Markets

Botanix ships first batch of sweat-stopper gel Sofdra to US patients

Cheyenne Enciso The West Australian
Tue, 17 December 2024 3:38PM [Comments](#) +

Cheyenne Enciso



📷 Botanix CEO Howie McKibbin, executive chairman Vince Ippolito and executive director Matt Callahan. Credit: Jackson Flindell/The West Australian

- WA biotech Botanix has shipped the first batch of its sweat-stopper gel to US patients six months after securing Food and Drug Administration approval.
- First prescriptions for its lead product Sofdra – used to treat primary axillary hyperhidrosis, or excessive underarm sweating, in adults and children aged 9 years and older – have been shipped directly to patients after successful diagnosis via tele-medicine and cleared insurance approvals.

On Tuesday, Botanix – headquartered in Perth, as well as in Philadelphia and Phoenix in the US – said this represented a significant milestone as it transitions into a revenue-generating commercial-stage pharmacy company.



HEALTH

Botanix gets FDA nod for sweat-stopper gel

Cheyenne Enciso



BIOTECH

Perth biotech Botanix now among the top 500 listed companies

Cheyenne Enciso

Sofdra was the first and only new chemical entity approved by the FDA to treat hyperhidrosis, a condition characterised by abnormally increased sweating and is the largest dermatology condition after acne and atopic dermatitis.

There are about 10 million patients in the US with primary axillary hyperhidrosis.

Following the FDA approval in June, Botanix raised \$70 million from institutional investors for 2.3 million new shares priced at 30¢ each.

The company at the time said the proceeds were set to be used to fund sales and marketing, manufacturing and support costs for Sofdra.

Botanix shares last traded at 38¢.